Valo Therapeutics: Developing Personalised Immunotherapies for Cancer

In recent years, there has been a transformative shift in the field of oncology with the emergence of cancer immunotherapy as a novel approach to cancer treatment. Unlike conventional methods like chemotherapy or radiation, which directly target cancer cells, immunotherapy utilizes the body's immune system to combat and eliminate cancer. This approach is especially promising in the context of cancer, a complex and formidable disease known for its ability to evade the immune system's defenses. Therapeutic strategies that activate the patient's immune system present a compelling avenue for more personalized and targeted treatment options.

European IP Helpdesk team recently published a case study “Developing personalised immunotherapies for cancer” showcasing how the ground-breaking research of Professor Vincenzo Cerullo and his group at the ImmunoViroTherapy Lab at Helsinki University led to the founding of the spin-out company Valo Therapeutics (ValoTx), setting out to make cancer immunotherapy more effective and accessible to patients.

Download the case study here.